Literature DB >> 15301726

[Heat shock protein 90: novel target for cancer therapy].

Yi Chen1, Jian Ding.   

Abstract

The molecular chaperone heat shock protein 90 (Hsp90) is important in maintaining the conformation, stability, and function of many proteins involved in cell surviving. Hsp90 is of interest as an anticancer drug target because of its importance in maintaining the function of key oncogenic client proteins. Hsp90 inhibitors also have shown promising antitumor activity in vitro and in vivo preclinical model systems. One Hsp90 inhibitor, 17-allylamio-17- desmethoxygeldanamycin (17-AAG), is currently in clinical trial.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15301726

Source DB:  PubMed          Journal:  Ai Zheng


  2 in total

1.  Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors.

Authors:  Junghee Kang; Adeela Kamal; Francis J Burrows; B Mark Evers; Dai H Chung
Journal:  Anticancer Res       Date:  2006 May-Jun       Impact factor: 2.480

2.  [The correlation between the up-regulation of Hsp90 and drug resistance to cisplatin in lung cancer cell line].

Authors:  Ting Liu; Xiaokun Wang; Lichuan Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.